Prothena Corp Public (PRTA) Common Equity (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Common Equity of $312.6 million for Q1 2026, down 28.57% year-over-year from $437.7 million in Q1 2025, and up 11.46% quarter-over-quarter from $280.5 million in Q4 2025.
Prothena Corp Public (PRTA) Common Equity (2012 - 2026) Analysis & Trends
Prothena Corp Public's Common Equity history runs 15 years deep, the most recent figure standing at $312.6 million for Q1 2026.
- In Q1 2026, Common Equity fell 28.57% year-over-year to $312.6 million; the TTM figure through Mar 2026 stood at $312.6 million (down 28.57% YoY), while the FY2025 annual figure was $280.5 million, down 42.4% from the prior year.
- Common Equity for Q1 2026 stood at $312.6 million, up from $280.5 million in the prior quarter.
- The five-year high for Common Equity was $622.0 million in Q4 2022, with the low at $280.5 million in Q4 2025.
- The 5-year median for Common Equity is $486.9 million (2024), against an average of $470.4 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 87.09% in 2022, then sank 44.8% in 2025.
- Prothena Corp Public's Common Equity stood at $622.0 million in 2022, then retreated by 9.75% to $561.4 million in 2023, then retreated by 13.26% to $486.9 million in 2024, then sank by 42.4% to $280.5 million in 2025, then climbed by 11.46% to $312.6 million in 2026.
- Business Quant data shows PRTA's Common Equity at $312.6 million in Q1 2026, $280.5 million in Q4 2025, and $295.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 286.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 286.89 Mn |
| Mar 31, 2026 | 312.62 Mn |
| Dec 31, 2025 | 280.47 Mn |
| Sep 30, 2025 | 294.99 Mn |
| Jun 30, 2025 | 324.33 Mn |
| Mar 31, 2025 | 437.68 Mn |
| Dec 31, 2024 | 486.93 Mn |
| Sep 30, 2024 | 534.36 Mn |
| Jun 30, 2024 | 581.92 Mn |
| Mar 31, 2024 | 502.40 Mn |
| Dec 31, 2023 | 561.37 Mn |
| Sep 30, 2023 | 617.23 Mn |
| Jun 30, 2023 | 581.68 Mn |
| Mar 31, 2023 | 607.41 Mn |
| Dec 31, 2022 | 622.04 Mn |
| Sep 30, 2022 | 404.65 Mn |
| Jun 30, 2022 | 407.30 Mn |
| Mar 31, 2022 | 438.89 Mn |
| Dec 31, 2021 | 466.04 Mn |
| Sep 30, 2021 | 490.47 Mn |